Cancer research has advanced significantly over the past century, yet a comprehensive understanding of the disease remains elusive. While the somatic mutation theory (SMT) has dominated the oncology field, emerging evidence highlights the critical roles of epigenetic regulation, metabolic reprogramming, stromal interactions, and host organism in cancer progression. Cancer is now recognized as a systemic perturbation involving complex genetic, epigenetic, and metabolic networks, where individual mutations contribute but do not exclusively define this condition. The “bottleneck” trajectory of cancer points rather to the activation of a default universal cellular survival process rather than a disease caused solely by random genetic alterations. Current therapies, including chemotherapy, targeted treatments, and immunotherapies, often show limited or transient effectiveness, especially in metastatic settings. Long-term survival in the metastatic setting remains rare, and immunotherapy has demonstrated potential only in specific cancers. Prevention and early detection are still the most effective strategies. Importantly, spontaneous regression of tumors suggests that immune-mediated control could play a significant role. This view proposes that cancer functions as a pathological symbiosis within the host, co-opting its biological infrastructure. Cancer is not merely a molecular disease but also a dynamic, systemic process intricately entangled with the organism. Beyond targeting cancer genes or cancer cells, future therapies must address the complex, bidirectional interactions between tumors and host systems—immune, vascular, endocrine, and nervous. Cancer exploits these networks for survival and dissemination, acting as a novel life form coevolving within its host. Like placentation and embryonic development, it co-opts immune tolerance and remodeling processes. Its clinical impact arises not only from cellular alterations but also from systemic disruptions, inflammation, and metabolic shifts. A shift in perspective is needed, viewing cancer not as a genetic anomaly but as a systemic, multilevel biological process. By emphasizing integrative, process-based therapies over molecular targeting and considering the temporal and environmental dynamics of cancer, we can better address its complexity. Artificial intelligence offers transformative potential, aiding in multi-omics integration, drug design, and predictive modeling; however, it remains limited by data quality and biological complexity. Importantly, cancer is also an existential condition associated with significant psychological and existential distress. Holistic oncology must integrate cancer-directed treatments with patient-centered empathy, addressing physical, emotional, and spiritual dimensions. Empowering patients and embracing integrative, organism-level perspectives are crucial to advancing meaningful, effective, and compassionate cancer care.

One Flew Over the Cancer’s Nest

章节
发表日期：

2025年

查看全文

Doru Paul

摘要

Cancer research has advanced significantly over the past century, yet a comprehensive understanding of the disease remains elusive. While the somatic mutation theory (SMT) has dominated the oncology field, emerging evidence highlights the critical roles of epigenetic regulation, metabolic reprogramming, stromal interactions, and host organism in cancer progression. Cancer is now recognized as a systemic perturbation involving complex genetic, epigenetic, and metabolic networks, where individual mutations contribute but do not exclusively define this condition. The “bottleneck” trajectory of cancer points rather to the activation of a default universal cellular survival process rather than a disease caused solely by random genetic alterations. Current therapies, including chemotherapy, targeted treatments, and immunotherapies, often show limited or transient effectiveness, especially in metastatic settings. Long-term survival in the metastatic setting remains rare, and immunotherapy has demonstrated potential only in specific cancers. Prevention and early detection are still the most effective strategies. Importantly, spontaneous regression of tumors suggests that immune-mediated control could play a significant role. This view proposes that cancer functions as a pathological symbiosis within the host, co-opting its biological infrastructure. Cancer is not merely a molecular disease but also a dynamic, systemic process intricately entangled with the organism. Beyond targeting cancer genes or cancer cells, future therapies must address the complex, bidirectional interactions between tumors and host systems—immune, vascular, endocrine, and nervous. Cancer exploits these networks for survival and dissemination, acting as a novel life form coevolving within its host. Like placentation and embryonic development, it co-opts immune tolerance and remodeling processes. Its clinical impact arises not only from cellular alterations but also from systemic disruptions, inflammation, and metabolic shifts. A shift in perspective is needed, viewing cancer not as a genetic anomaly but as a systemic, multilevel biological process. By emphasizing integrative, process-based therapies over molecular targeting and considering the temporal and environmental dynamics of cancer, we can better address its complexity. Artificial intelligence offers transformative potential, aiding in multi-omics integration, drug design, and predictive modeling; however, it remains limited by data quality and biological complexity. Importantly, cancer is also an existential condition associated with significant psychological and existential distress. Holistic oncology must integrate cancer-directed treatments with patient-centered empathy, addressing physical, emotional, and spiritual dimensions. Empowering patients and embracing integrative, organism-level perspectives are crucial to advancing meaningful, effective, and compassionate cancer care.